Spoken Alpha
Replimune Group, Inc.
Replimune Group, Inc. develops oncolytic immunotherapies—viruses engineered to selectively replicate in and kill tumor cells while triggering anti-tumor immune responses.
Replimune Group, Inc is a Healthcare company operating in Biotechnology with a $1.22B market cap.
Most recent reported earnings: Q2 FY2027 (Nov 4, 2026).
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for REPL.
$ curl https://api.spokenalpha.com/v1/companies/REPLFAQ
Spoken Alpha indexes REPL's earnings call transcripts at https://spokenalpha.com/companies/REPL. Each call links to attributed speakers and parsed analyst Q&A.
Replimune Group, Inc. (REPL) held its most recent earnings call on 2025-05-22, covering fiscal Q4 2025.
Replimune Group, Inc. (REPL) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2027 | 2026-11-04 | — | $-0.70 | — | — | — | — | EODHD |
| Q1 FY2027 | 2026-08-13 | $-0.72 | $-0.72 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2026 | 2026-06-28 | $-0.76 | $-0.73 | -4.1% | $0 | — | — | EODHD |
| Q3 FY2026 | 2026-02-02 | $-0.77 | $-0.82 | +6.1% | $0 | — | — | EODHD |
| Q2 FY2026 | 2025-11-05 | $-0.90 | $-0.79 | -13.9% | $0 | — | — | EODHD |
| Q1 FY2026 | 2025-08-06 | $-0.95 | $-0.83 | -14.5% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-05-21 | $-0.82 | $-0.69 | -18.8% | $1.5M | — | — | EODHD |
| Q3 FY2025 | 2025-02-11 | $-0.79 | $-0.72 | -9.7% | $0 | — | — | EODHD |
| Q2 FY2025 | 2024-11-11 | $-0.68 | $-0.74 | +8.1% | $0 | — | — | EODHD |
| Q1 FY2025 | 2024-08-07 | $-0.78 | $-0.83 | +6.0% | $0 | — | — | EODHD |
| Q4 FY2024 | 2024-05-15 | $-0.25 | $-0.80 | +68.8% | $4.0M | — | — | EODHD |
| Q3 FY2024 | 2024-02-07 | $-0.77 | $-0.93 | +17.2% | $0 | — | — | EODHD |
| Q2 FY2024 | 2023-11-06 | $-0.90 | $-0.89 | -1.1% | $0 | — | — | EODHD |
| Q1 FY2024 | 2023-08-02 | $-0.75 | $-0.84 | +10.7% | $0 | — | — | EODHD |
| Q4 FY2023 | 2023-05-17 | $-0.74 | $-0.66 | -12.1% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-02-08 | $-0.69 | $-0.74 | +6.8% | $0 | — | — | EODHD |
| Q2 FY2023 | 2022-11-02 | $-0.79 | $-0.76 | -4.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2022-08-03 | $-0.78 | $-0.56 | -39.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2022-05-18 | $-0.60 | $-0.60 | 0.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-02-02 | $-0.57 | $-0.57 | 0.0% | $0 | — | — | EODHD |
Source: EODHD. REPL reported actuals as published; sparse fields render as —.